{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-210794","form_type":"8-K","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.228844+00:00","generated_at":"2026-06-11T14:17:51.475935+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CalciMedica updates biz description with CARPO trial expansion, AKI plans, recasted financials","bullets":["CARPO Phase 2b in AP+SIRS expanded to India; topline results expected first half 2024.","CRSPA Phase 1/2 in pediatric AIPT completed first cohort; data publication expected Q4 2023.","AKI plan: IND submission H2 2023; Phase 2 trial H1 2024 subject to additional funding.","CARDEA trial showed 56% relative mortality reduction at 30 days (p=0.0165) in severe COVID-19 pneumonia.","Audited recasted financial statements of Private CalciMedica as of Dec 31, 2022 and 2021 filed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-210794","json":"https://secwatch.observer/filing/0001193125-23-210794.json","markdown":"https://secwatch.observer/filing/0001193125-23-210794.md","text":"https://secwatch.observer/filing/0001193125-23-210794.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523210794/0001193125-23-210794-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523210794/d441914d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T14:17:51.475935+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}